Your session is about to expire
← Back to Search
Lung Protective Ventilation for Brain Injury (NEUROVENT Trial)
N/A
Waitlist Available
Led By Colin K Grissom, MD
Research Sponsored by Colin Grissom
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day of admission to day of discharge, an average of 10 days
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a computerized ventilator protocol in iCentra that is designed to improve outcomes for patients with acute brain injury by targeting a normal partial pressure of carbon dioxide while using the lowest ventilator volume required.
Who is the study for?
This trial is for adults (18+) with acute brain injury, either from non-traumatic causes like stroke or anoxic brain injury, or from traumatic events. They must be starting mechanical ventilation in the emergency department or ICU at an Intermountain Healthcare hospital.
What is being tested?
The study tests a computerized ventilator protocol aiming to maintain normal carbon dioxide levels in blood while using the lowest necessary ventilator volume. It's designed to prevent further lung damage and improve outcomes for patients with acute brain injuries.
What are the potential side effects?
While not explicitly listed, potential side effects may include discomfort due to lower ventilator volumes and possible complications if optimal carbon dioxide levels are not maintained.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day of admission to day of discharge, an average of 10 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day of admission to day of discharge, an average of 10 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Average number of protocol deviations for all subjects (protocol compliance)
Health Care Utilization
Hospital Discharge Disposition
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Lung Protective VentilationExperimental Treatment1 Intervention
Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lung Protective Ventilation
2018
N/A
~20
Find a Location
Who is running the clinical trial?
Colin GrissomLead Sponsor
Colin K Grissom, MDPrincipal InvestigatorIntermountain Health Care, Inc.